Shanghai Haoyuan Chemexpress Co., Ltd. (SHSE:688131) Not Flying Under The Radar
Feb 11
Have your own idea? Try our Stock Screener
Chinese (SSE) Clinical Research and Equipment Industry Analysis
UpdatedFeb 19, 2025
DataAggregated Company Financials
Companies26
- 7D5.0%
- 3M5.8%
- 1Y15.8%
- YTDn/a
The Clinical Research and Equipment industry is up 6.2% in the last week, with WuXi AppTec up 6.9%. In the same time, Beijing Hotgen Biotech was down 7.5%. This takes the industry's 12 month performance to a gain of 22%. Looking forward, earnings are forecast to grow by 31% annually.
Industry Valuation and Performance
Has the Chinese Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 19 Feb 2025 | CN¥412.6b | CN¥88.1b | CN¥11.2b | 41.8x | 36.7x | 4.7x |
| Fri, 17 Jan 2025 | CN¥353.2b | CN¥88.1b | CN¥11.2b | 36.3x | 31.4x | 4x |
| Sun, 15 Dec 2024 | CN¥388.6b | CN¥87.8b | CN¥11.2b | 40.1x | 34.7x | 4.4x |
| Tue, 12 Nov 2024 | CN¥410.5b | CN¥87.8b | CN¥11.2b | 44.8x | 36.7x | 4.7x |
| Thu, 10 Oct 2024 | CN¥394.6b | CN¥88.2b | CN¥12.4b | 35.5x | 31.9x | 4.5x |
| Sat, 07 Sep 2024 | CN¥274.1b | CN¥87.1b | CN¥12.3b | 27.9x | 22.3x | 3.1x |
| Mon, 05 Aug 2024 | CN¥301.0b | CN¥87.6b | CN¥12.6b | 27.9x | 24x | 3.4x |
| Wed, 03 Jul 2024 | CN¥274.6b | CN¥88.3b | CN¥13.4b | 24.3x | 20.5x | 3.1x |
| Fri, 31 May 2024 | CN¥307.5b | CN¥88.3b | CN¥13.4b | 27.5x | 23x | 3.5x |
| Sun, 28 Apr 2024 | CN¥317.5b | CN¥90.2b | CN¥14.4b | 30.4x | 22x | 3.5x |
| Tue, 26 Mar 2024 | CN¥345.9b | CN¥90.4b | CN¥15.6b | 32.4x | 22.2x | 3.8x |
| Thu, 22 Feb 2024 | CN¥355.5b | CN¥91.1b | CN¥16.1b | 31.2x | 22.1x | 3.9x |
| Sat, 20 Jan 2024 | CN¥452.3b | CN¥91.1b | CN¥16.1b | 35.4x | 28.1x | 5x |
| Mon, 18 Dec 2023 | CN¥479.2b | CN¥91.1b | CN¥16.1b | 37.3x | 29.8x | 5.3x |
| Wed, 15 Nov 2023 | CN¥550.9b | CN¥91.1b | CN¥16.1b | 40.1x | 34.3x | 6x |
| Fri, 13 Oct 2023 | CN¥544.2b | CN¥92.0b | CN¥18.3b | 36.4x | 29.7x | 5.9x |
| Sun, 10 Sep 2023 | CN¥470.0b | CN¥91.9b | CN¥18.3b | 32.3x | 25.7x | 5.1x |
| Tue, 08 Aug 2023 | CN¥481.8b | CN¥91.8b | CN¥18.5b | 34.8x | 26.1x | 5.2x |
| Thu, 06 Jul 2023 | CN¥460.3b | CN¥91.3b | CN¥18.5b | 34.8x | 24.9x | 5x |
| Sat, 03 Jun 2023 | CN¥500.0b | CN¥91.3b | CN¥18.5b | 38.6x | 27.1x | 5.5x |
| Mon, 01 May 2023 | CN¥514.4b | CN¥92.3b | CN¥18.9b | 43.1x | 27.2x | 5.6x |
| Wed, 29 Mar 2023 | CN¥599.7b | CN¥90.2b | CN¥19.9b | 49.2x | 30.2x | 6.6x |
| Fri, 24 Feb 2023 | CN¥624.7b | CN¥86.6b | CN¥20.8b | 53.7x | 30x | 7.2x |
| Sun, 22 Jan 2023 | CN¥713.5b | CN¥86.6b | CN¥20.8b | 60.6x | 34.3x | 8.2x |
| Tue, 20 Dec 2022 | CN¥566.3b | CN¥86.6b | CN¥20.8b | 47.1x | 27.2x | 6.5x |
| Thu, 17 Nov 2022 | CN¥655.6b | CN¥86.5b | CN¥20.8b | 56.5x | 31.5x | 7.6x |
| Sat, 15 Oct 2022 | CN¥585.1b | CN¥78.2b | CN¥16.9b | 48.8x | 34.6x | 7.5x |
| Mon, 12 Sep 2022 | CN¥614.4b | CN¥77.8b | CN¥17.0b | 49.6x | 36.1x | 7.9x |
| Wed, 10 Aug 2022 | CN¥638.6b | CN¥73.3b | CN¥17.1b | 67.8x | 37.4x | 8.7x |
| Fri, 08 Jul 2022 | CN¥740.3b | CN¥69.0b | CN¥15.2b | 74.4x | 48.7x | 10.7x |
| Sun, 05 Jun 2022 | CN¥577.0b | CN¥69.0b | CN¥15.2b | 55.6x | 38x | 8.4x |
| Tue, 03 May 2022 | CN¥619.7b | CN¥68.4b | CN¥15.1b | 59x | 41x | 9.1x |
| Thu, 31 Mar 2022 | CN¥684.3b | CN¥62.7b | CN¥15.0b | 65.8x | 45.6x | 10.9x |
| Sat, 26 Feb 2022 | CN¥606.5b | CN¥59.2b | CN¥13.3b | 64.6x | 45.7x | 10.2x |
Price to Earnings Ratio
45.7x
Current Industry PE
- Investors are optimistic on the Chinese Life Sciences Tools and Services industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 37.8x which is higher than its 3-year average PE of 30.4x.
- The 3-year average PS ratio of 5.9x is higher than the industry's current PS ratio of 4.8x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have declined 5.3% per year over the last three years.
- Meanwhile revenues for these companies have grown 14% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Comparison
How does Chinese Clinical Research and Equipment compare with similar industries?
| CN Market | -0.076% | |
| Healthcare | 0.59% | |
| Life Sciences | 4.96% | |
| Clinical Research and Equipment | 4.96% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 603259 WuXi AppTec | CN¥62.50 | 8.5% +CN¥14.1b | 16.3% | PE22.4x | |
| 688114 MGI Tech | CN¥69.95 | 9.6% +CN¥2.5b | -3.5% | PS11.2x | |
| 688315 Novogene | CN¥19.68 | 35.3% +CN¥2.1b | 28.3% | PE42.6x | |
| 300759 Pharmaron Beijing | CN¥26.88 | 3.3% +CN¥1.5b | 22.5% | PE25.3x | |
| 301230 PharmaResources (Shanghai) | CN¥39.42 | 24.1% +CN¥1.1b | 82.8% | PE782.5x |
